Fig. 3

Gene silencing of ADAM17 reduced infarct size and improve cardiac function in MI mice. A Schematic diagram of the experimental design. The ADAM17 inhibitor TAPI-1 or a comparable amount of DMSO were gavaged into mice on days 1, 3, 5, 7, and 14. Mice were sacrificed on day 30 after the first treatment. B RT-qPCR analysis of the expression of ADAM17 after administration. C Immunofluorescence of cTNT (red), ADAM17 (green) and DAPI (blue) in the infarcted area of the MI mice heart. D, E Masson trichrome staining of heart cross-sections (D). Scar circumference was measured as the percentage over the area of LV myocardium (E). F–J Echocardiographic analysis images on 30 days after treatment (F). Statistical charts for LVIDd(G), LVID(H), EF (I) and FS (J) are shown. K–L WGA staining to measure cardiomyocyte surface area and its quantification. M RT-qPCR analysis of the expression of ANP, BNP, and MyHC of the MI mice Myocardium. N = 6 biological replicates. Data shown as mean ± SEM. Derived by two-sample t-test, *P < 0.05; **P < 0.01, ***P < 0.001